White Paper: Spray Drying Biologics: An Alternative To Freeze Drying

By Dr. Richard Johnson, Chief Scientific Officer

Drug products containing active biological ingredients represent one of the most significant and rapidly expanding sectors of the pharmaceutical industry. The biologics market is projected to achieve sales of USD 429.5 billion in 2024, with expectations to reach USD 601.3 billion by 2029, reflecting a compound annual growth rate (CAGR) of 6.96% between 2024 and 2029.

Dr. Richard Johnson, Chief Scientific Officer at Upperton Pharma Solutions, discusses the growth and complexity of dosage forms that incorporate biologics, as well as the alternative drying technologies that offer viable solutions beyond traditional freeze-drying methods.

Key topics covered in the white paper include the necessity of drying technologies to stabilize drug products containing biologics, an overview of freeze-drying as the established technology for producing dry powder biologics, and the advantages of spray drying as a cost-effective alternative. Additionally, the white paper addresses the challenge of creating stable dry powders while maintaining the tertiary structure of the active ingredients and explores the spray-drying of complex liposomal formulations that encapsulate proteins and peptides.